nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—Skin lesion—Capecitabine—esophageal cancer	0.0283	0.0468	CcSEcCtD
Labetalol—Depressed mood—Capecitabine—esophageal cancer	0.0165	0.0273	CcSEcCtD
Labetalol—Dobutamine—CA2—esophageal cancer	0.0161	0.186	CrCbGaD
Labetalol—Joint swelling—Capecitabine—esophageal cancer	0.015	0.0249	CcSEcCtD
Labetalol—Formoterol—CYP2A6—esophageal cancer	0.0122	0.141	CrCbGaD
Labetalol—Arformoterol—CYP2A6—esophageal cancer	0.0122	0.141	CrCbGaD
Labetalol—Loss of libido—Methotrexate—esophageal cancer	0.0119	0.0197	CcSEcCtD
Labetalol—Raised liver function tests—Methotrexate—esophageal cancer	0.0119	0.0197	CcSEcCtD
Labetalol—Respiratory distress—Capecitabine—esophageal cancer	0.0116	0.0192	CcSEcCtD
Labetalol—Pain—Carboplatin—esophageal cancer	0.0104	0.0172	CcSEcCtD
Labetalol—Throat sore—Capecitabine—esophageal cancer	0.0102	0.0169	CcSEcCtD
Labetalol—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.0101	0.0168	CcSEcCtD
Labetalol—Wheezing—Cisplatin—esophageal cancer	0.00972	0.0161	CcSEcCtD
Labetalol—Body temperature increased—Carboplatin—esophageal cancer	0.00962	0.0159	CcSEcCtD
Labetalol—Tingling sensation—Capecitabine—esophageal cancer	0.00918	0.0152	CcSEcCtD
Labetalol—Salsalate—PTGS1—esophageal cancer	0.00842	0.0975	CrCbGaD
Labetalol—Oropharyngeal pain—Capecitabine—esophageal cancer	0.00811	0.0134	CcSEcCtD
Labetalol—Nasal congestion—Cisplatin—esophageal cancer	0.00797	0.0132	CcSEcCtD
Labetalol—Amnesia—Cisplatin—esophageal cancer	0.00773	0.0128	CcSEcCtD
Labetalol—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00751	0.0124	CcSEcCtD
Labetalol—Fenoprofen—PTGS1—esophageal cancer	0.00696	0.0806	CrCbGaD
Labetalol—Dry eye—Capecitabine—esophageal cancer	0.00681	0.0113	CcSEcCtD
Labetalol—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00664	0.011	CcSEcCtD
Labetalol—Cramp muscle—Cisplatin—esophageal cancer	0.00654	0.0108	CcSEcCtD
Labetalol—Sleep disorder—Capecitabine—esophageal cancer	0.00619	0.0102	CcSEcCtD
Labetalol—Sweating increased—Cisplatin—esophageal cancer	0.00612	0.0101	CcSEcCtD
Labetalol—Amnesia—Capecitabine—esophageal cancer	0.0057	0.00943	CcSEcCtD
Labetalol—Mirabegron—ABCB1—esophageal cancer	0.00566	0.0656	CrCbGaD
Labetalol—Cardiac failure—Capecitabine—esophageal cancer	0.00549	0.00908	CcSEcCtD
Labetalol—Lethargy—Capecitabine—esophageal cancer	0.00546	0.00904	CcSEcCtD
Labetalol—Bradycardia—Cisplatin—esophageal cancer	0.00512	0.00847	CcSEcCtD
Labetalol—Urinary retention—Capecitabine—esophageal cancer	0.00509	0.00843	CcSEcCtD
Labetalol—Mood swings—Capecitabine—esophageal cancer	0.00507	0.0084	CcSEcCtD
Labetalol—Liver function test abnormal—Capecitabine—esophageal cancer	0.00494	0.00818	CcSEcCtD
Labetalol—Abdominal pain upper—Capecitabine—esophageal cancer	0.00489	0.00809	CcSEcCtD
Labetalol—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00489	0.00809	CcSEcCtD
Labetalol—Visual impairment—Cisplatin—esophageal cancer	0.00484	0.00802	CcSEcCtD
Labetalol—Salsalate—PTGS2—esophageal cancer	0.00482	0.0557	CrCbGaD
Labetalol—Flushing—Cisplatin—esophageal cancer	0.00466	0.00772	CcSEcCtD
Labetalol—Bronchospasm—Capecitabine—esophageal cancer	0.00455	0.00753	CcSEcCtD
Labetalol—Flurbiprofen—PTGS1—esophageal cancer	0.00454	0.0526	CrCbGaD
Labetalol—Sweating increased—Capecitabine—esophageal cancer	0.00451	0.00746	CcSEcCtD
Labetalol—Angina pectoris—Capecitabine—esophageal cancer	0.00451	0.00746	CcSEcCtD
Labetalol—Alopecia—Cisplatin—esophageal cancer	0.00444	0.00735	CcSEcCtD
Labetalol—Erythema—Cisplatin—esophageal cancer	0.00437	0.00724	CcSEcCtD
Labetalol—Dysuria—Capecitabine—esophageal cancer	0.00433	0.00716	CcSEcCtD
Labetalol—Muscle spasms—Cisplatin—esophageal cancer	0.00421	0.00696	CcSEcCtD
Labetalol—Vision blurred—Cisplatin—esophageal cancer	0.00412	0.00682	CcSEcCtD
Labetalol—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.00412	0.00682	CcSEcCtD
Labetalol—Depression—Capecitabine—esophageal cancer	0.00411	0.00681	CcSEcCtD
Labetalol—Ketoprofen—PTGS1—esophageal cancer	0.00411	0.0476	CrCbGaD
Labetalol—Tremor—Cisplatin—esophageal cancer	0.0041	0.00678	CcSEcCtD
Labetalol—Lethargy—Methotrexate—esophageal cancer	0.00407	0.00673	CcSEcCtD
Labetalol—Ill-defined disorder—Cisplatin—esophageal cancer	0.00406	0.00672	CcSEcCtD
Labetalol—Jaundice—Capecitabine—esophageal cancer	0.00402	0.00666	CcSEcCtD
Labetalol—Fenoprofen—PTGS2—esophageal cancer	0.00398	0.0461	CrCbGaD
Labetalol—Malaise—Cisplatin—esophageal cancer	0.00395	0.00653	CcSEcCtD
Labetalol—Epistaxis—Capecitabine—esophageal cancer	0.00389	0.00644	CcSEcCtD
Labetalol—Agranulocytosis—Capecitabine—esophageal cancer	0.00385	0.00637	CcSEcCtD
Labetalol—Mood swings—Methotrexate—esophageal cancer	0.00378	0.00625	CcSEcCtD
Labetalol—Bradycardia—Capecitabine—esophageal cancer	0.00377	0.00624	CcSEcCtD
Labetalol—Hepatitis—Capecitabine—esophageal cancer	0.0037	0.00613	CcSEcCtD
Labetalol—Hypoaesthesia—Capecitabine—esophageal cancer	0.00369	0.0061	CcSEcCtD
Labetalol—Liver function test abnormal—Methotrexate—esophageal cancer	0.00368	0.00609	CcSEcCtD
Labetalol—Discomfort—Cisplatin—esophageal cancer	0.00368	0.00609	CcSEcCtD
Labetalol—Oedema peripheral—Capecitabine—esophageal cancer	0.00365	0.00604	CcSEcCtD
Labetalol—Oedema—Cisplatin—esophageal cancer	0.00357	0.00591	CcSEcCtD
Labetalol—Anaphylactic shock—Cisplatin—esophageal cancer	0.00357	0.00591	CcSEcCtD
Labetalol—Visual impairment—Capecitabine—esophageal cancer	0.00357	0.00591	CcSEcCtD
Labetalol—Hyperhidrosis—Cisplatin—esophageal cancer	0.00345	0.00571	CcSEcCtD
Labetalol—Flushing—Capecitabine—esophageal cancer	0.00344	0.00569	CcSEcCtD
Labetalol—Hypotension—Cisplatin—esophageal cancer	0.00334	0.00552	CcSEcCtD
Labetalol—Alopecia—Capecitabine—esophageal cancer	0.00327	0.00542	CcSEcCtD
Labetalol—Mental disorder—Capecitabine—esophageal cancer	0.00325	0.00537	CcSEcCtD
Labetalol—Erythema—Capecitabine—esophageal cancer	0.00322	0.00534	CcSEcCtD
Labetalol—Dysuria—Methotrexate—esophageal cancer	0.00322	0.00533	CcSEcCtD
Labetalol—Paraesthesia—Cisplatin—esophageal cancer	0.00321	0.00531	CcSEcCtD
Labetalol—Dyspnoea—Cisplatin—esophageal cancer	0.00318	0.00527	CcSEcCtD
Labetalol—Erectile dysfunction—Methotrexate—esophageal cancer	0.00317	0.00525	CcSEcCtD
Labetalol—Muscle spasms—Capecitabine—esophageal cancer	0.0031	0.00513	CcSEcCtD
Labetalol—Drowsiness—Methotrexate—esophageal cancer	0.00307	0.00508	CcSEcCtD
Labetalol—Depression—Methotrexate—esophageal cancer	0.00306	0.00507	CcSEcCtD
Labetalol—Pain—Cisplatin—esophageal cancer	0.00305	0.00505	CcSEcCtD
Labetalol—Vision blurred—Capecitabine—esophageal cancer	0.00304	0.00503	CcSEcCtD
Labetalol—Tremor—Capecitabine—esophageal cancer	0.00302	0.005	CcSEcCtD
Labetalol—Ill-defined disorder—Capecitabine—esophageal cancer	0.00299	0.00495	CcSEcCtD
Labetalol—Sweating—Methotrexate—esophageal cancer	0.00295	0.00487	CcSEcCtD
Labetalol—Feeling abnormal—Cisplatin—esophageal cancer	0.00294	0.00487	CcSEcCtD
Labetalol—Malaise—Capecitabine—esophageal cancer	0.00291	0.00481	CcSEcCtD
Labetalol—Epistaxis—Methotrexate—esophageal cancer	0.0029	0.0048	CcSEcCtD
Labetalol—Vertigo—Capecitabine—esophageal cancer	0.0029	0.0048	CcSEcCtD
Labetalol—Syncope—Capecitabine—esophageal cancer	0.00289	0.00479	CcSEcCtD
Labetalol—Agranulocytosis—Methotrexate—esophageal cancer	0.00287	0.00474	CcSEcCtD
Labetalol—Palpitations—Capecitabine—esophageal cancer	0.00285	0.00472	CcSEcCtD
Labetalol—Loss of consciousness—Capecitabine—esophageal cancer	0.00283	0.00469	CcSEcCtD
Labetalol—Body temperature increased—Cisplatin—esophageal cancer	0.00282	0.00467	CcSEcCtD
Labetalol—Hypertension—Capecitabine—esophageal cancer	0.00278	0.00461	CcSEcCtD
Labetalol—Hepatitis—Methotrexate—esophageal cancer	0.00276	0.00456	CcSEcCtD
Labetalol—Discomfort—Capecitabine—esophageal cancer	0.00271	0.00449	CcSEcCtD
Labetalol—Visual impairment—Methotrexate—esophageal cancer	0.00266	0.0044	CcSEcCtD
Labetalol—Confusional state—Capecitabine—esophageal cancer	0.00265	0.00439	CcSEcCtD
Labetalol—Oedema—Capecitabine—esophageal cancer	0.00263	0.00436	CcSEcCtD
Labetalol—Hypersensitivity—Cisplatin—esophageal cancer	0.00263	0.00435	CcSEcCtD
Labetalol—Flurbiprofen—PTGS2—esophageal cancer	0.0026	0.0301	CrCbGaD
Labetalol—Shock—Capecitabine—esophageal cancer	0.00259	0.00429	CcSEcCtD
Labetalol—Asthenia—Cisplatin—esophageal cancer	0.00256	0.00424	CcSEcCtD
Labetalol—Hyperhidrosis—Capecitabine—esophageal cancer	0.00254	0.00421	CcSEcCtD
Labetalol—Propafenone—ABCB1—esophageal cancer	0.00253	0.0293	CrCbGaD
Labetalol—Hypotension—Capecitabine—esophageal cancer	0.00246	0.00407	CcSEcCtD
Labetalol—Diarrhoea—Cisplatin—esophageal cancer	0.00244	0.00404	CcSEcCtD
Labetalol—Alopecia—Methotrexate—esophageal cancer	0.00244	0.00403	CcSEcCtD
Labetalol—Mental disorder—Methotrexate—esophageal cancer	0.00242	0.004	CcSEcCtD
Labetalol—Erythema—Methotrexate—esophageal cancer	0.0024	0.00397	CcSEcCtD
Labetalol—Paraesthesia—Capecitabine—esophageal cancer	0.00236	0.00391	CcSEcCtD
Labetalol—Ketoprofen—PTGS2—esophageal cancer	0.00235	0.0272	CrCbGaD
Labetalol—Dyspnoea—Capecitabine—esophageal cancer	0.00235	0.00388	CcSEcCtD
Labetalol—Dyspepsia—Capecitabine—esophageal cancer	0.00232	0.00383	CcSEcCtD
Labetalol—Vomiting—Cisplatin—esophageal cancer	0.00227	0.00376	CcSEcCtD
Labetalol—Fatigue—Capecitabine—esophageal cancer	0.00227	0.00376	CcSEcCtD
Labetalol—Vision blurred—Methotrexate—esophageal cancer	0.00226	0.00374	CcSEcCtD
Labetalol—Rash—Cisplatin—esophageal cancer	0.00225	0.00373	CcSEcCtD
Labetalol—Pain—Capecitabine—esophageal cancer	0.00225	0.00373	CcSEcCtD
Labetalol—Constipation—Capecitabine—esophageal cancer	0.00225	0.00373	CcSEcCtD
Labetalol—Dermatitis—Cisplatin—esophageal cancer	0.00225	0.00372	CcSEcCtD
Labetalol—Ill-defined disorder—Methotrexate—esophageal cancer	0.00223	0.00369	CcSEcCtD
Labetalol—Feeling abnormal—Capecitabine—esophageal cancer	0.00217	0.00359	CcSEcCtD
Labetalol—Malaise—Methotrexate—esophageal cancer	0.00216	0.00358	CcSEcCtD
Labetalol—Vertigo—Methotrexate—esophageal cancer	0.00216	0.00357	CcSEcCtD
Labetalol—Gastrointestinal pain—Capecitabine—esophageal cancer	0.00215	0.00356	CcSEcCtD
Labetalol—Nausea—Cisplatin—esophageal cancer	0.00212	0.00351	CcSEcCtD
Labetalol—Urticaria—Capecitabine—esophageal cancer	0.00209	0.00346	CcSEcCtD
Labetalol—Abdominal pain—Capecitabine—esophageal cancer	0.00208	0.00344	CcSEcCtD
Labetalol—Body temperature increased—Capecitabine—esophageal cancer	0.00208	0.00344	CcSEcCtD
Labetalol—Discomfort—Methotrexate—esophageal cancer	0.00202	0.00334	CcSEcCtD
Labetalol—Confusional state—Methotrexate—esophageal cancer	0.00198	0.00327	CcSEcCtD
Labetalol—Anaphylactic shock—Methotrexate—esophageal cancer	0.00196	0.00324	CcSEcCtD
Labetalol—Hypersensitivity—Capecitabine—esophageal cancer	0.00194	0.00321	CcSEcCtD
Labetalol—Hyperhidrosis—Methotrexate—esophageal cancer	0.00189	0.00313	CcSEcCtD
Labetalol—Asthenia—Capecitabine—esophageal cancer	0.00189	0.00313	CcSEcCtD
Labetalol—Pruritus—Capecitabine—esophageal cancer	0.00186	0.00308	CcSEcCtD
Labetalol—Hypotension—Methotrexate—esophageal cancer	0.00183	0.00303	CcSEcCtD
Labetalol—Diarrhoea—Capecitabine—esophageal cancer	0.0018	0.00298	CcSEcCtD
Labetalol—Paraesthesia—Methotrexate—esophageal cancer	0.00176	0.00291	CcSEcCtD
Labetalol—Dyspnoea—Methotrexate—esophageal cancer	0.00175	0.00289	CcSEcCtD
Labetalol—Somnolence—Methotrexate—esophageal cancer	0.00174	0.00288	CcSEcCtD
Labetalol—Dizziness—Capecitabine—esophageal cancer	0.00174	0.00288	CcSEcCtD
Labetalol—Dyspepsia—Methotrexate—esophageal cancer	0.00172	0.00285	CcSEcCtD
Labetalol—Fatigue—Methotrexate—esophageal cancer	0.00169	0.0028	CcSEcCtD
Labetalol—Pain—Methotrexate—esophageal cancer	0.00168	0.00277	CcSEcCtD
Labetalol—Vomiting—Capecitabine—esophageal cancer	0.00167	0.00277	CcSEcCtD
Labetalol—Rash—Capecitabine—esophageal cancer	0.00166	0.00275	CcSEcCtD
Labetalol—Dermatitis—Capecitabine—esophageal cancer	0.00166	0.00274	CcSEcCtD
Labetalol—Headache—Capecitabine—esophageal cancer	0.00165	0.00273	CcSEcCtD
Labetalol—Feeling abnormal—Methotrexate—esophageal cancer	0.00161	0.00267	CcSEcCtD
Labetalol—Gastrointestinal pain—Methotrexate—esophageal cancer	0.0016	0.00265	CcSEcCtD
Labetalol—Nausea—Capecitabine—esophageal cancer	0.00156	0.00259	CcSEcCtD
Labetalol—Urticaria—Methotrexate—esophageal cancer	0.00156	0.00258	CcSEcCtD
Labetalol—Abdominal pain—Methotrexate—esophageal cancer	0.00155	0.00256	CcSEcCtD
Labetalol—Body temperature increased—Methotrexate—esophageal cancer	0.00155	0.00256	CcSEcCtD
Labetalol—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.00149	0.00482	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—GNG7—esophageal cancer	0.00149	0.0048	CbGpPWpGaD
Labetalol—ADRB2—Arf6 signaling events—EGFR—esophageal cancer	0.00148	0.0048	CbGpPWpGaD
Labetalol—Hypersensitivity—Methotrexate—esophageal cancer	0.00144	0.00239	CcSEcCtD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.00144	0.00466	CbGpPWpGaD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.00142	0.00459	CbGpPWpGaD
Labetalol—Asthenia—Methotrexate—esophageal cancer	0.00141	0.00233	CcSEcCtD
Labetalol—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.0014	0.00453	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—ADH7—esophageal cancer	0.00139	0.00449	CbGpPWpGaD
Labetalol—Pruritus—Methotrexate—esophageal cancer	0.00139	0.00229	CcSEcCtD
Labetalol—ADRB3—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00136	0.0044	CbGpPWpGaD
Labetalol—Diarrhoea—Methotrexate—esophageal cancer	0.00134	0.00222	CcSEcCtD
Labetalol—ADRB3—GPCR ligand binding—CXCL2—esophageal cancer	0.00131	0.00423	CbGpPWpGaD
Labetalol—Dizziness—Methotrexate—esophageal cancer	0.0013	0.00214	CcSEcCtD
Labetalol—ADRB3—Signaling Pathways—GDI2—esophageal cancer	0.00125	0.00403	CbGpPWpGaD
Labetalol—Vomiting—Methotrexate—esophageal cancer	0.00125	0.00206	CcSEcCtD
Labetalol—Rash—Methotrexate—esophageal cancer	0.00124	0.00204	CcSEcCtD
Labetalol—Dermatitis—Methotrexate—esophageal cancer	0.00123	0.00204	CcSEcCtD
Labetalol—Headache—Methotrexate—esophageal cancer	0.00123	0.00203	CcSEcCtD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.00123	0.00396	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—ADH1B—esophageal cancer	0.00122	0.00394	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—ANXA1—esophageal cancer	0.00122	0.00394	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—SST—esophageal cancer	0.00118	0.00383	CbGpPWpGaD
Labetalol—Nausea—Methotrexate—esophageal cancer	0.00116	0.00193	CcSEcCtD
Labetalol—ADRB3—GPCR ligand binding—GHRL—esophageal cancer	0.00115	0.00373	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00115	0.00372	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00113	0.00366	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00112	0.00361	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.00105	0.0034	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.00104	0.00336	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00102	0.0033	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000999	0.00323	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—AKAP13—esophageal cancer	0.000966	0.00312	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000949	0.00307	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000928	0.003	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000923	0.00298	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000903	0.00292	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KMT2D—esophageal cancer	0.000902	0.00292	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.0009	0.00291	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000889	0.00287	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PDE4D—esophageal cancer	0.000883	0.00285	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GNG7—esophageal cancer	0.000882	0.00285	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00088	0.00284	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—AKAP13—esophageal cancer	0.000877	0.00283	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00087	0.00281	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GNG7—esophageal cancer	0.000863	0.00279	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.000859	0.00278	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GNG7—esophageal cancer	0.00084	0.00272	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.000817	0.00264	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000808	0.00261	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.000807	0.00261	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ADCYAP1—esophageal cancer	0.000804	0.0026	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PDE4D—esophageal cancer	0.000802	0.00259	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00079	0.00255	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—CXCL2—esophageal cancer	0.000777	0.00251	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000765	0.00247	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GNG7—esophageal cancer	0.000763	0.00247	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—CXCL2—esophageal cancer	0.00076	0.00246	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GDI2—esophageal cancer	0.00074	0.00239	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CXCL2—esophageal cancer	0.00074	0.00239	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—WWOX—esophageal cancer	0.000735	0.00238	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GDI2—esophageal cancer	0.000724	0.00234	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—ANXA1—esophageal cancer	0.000723	0.00234	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—ANXA1—esophageal cancer	0.000707	0.00228	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—SST—esophageal cancer	0.000703	0.00227	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FKBP1A—esophageal cancer	0.000699	0.00226	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—ANXA1—esophageal cancer	0.000688	0.00222	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—SST—esophageal cancer	0.000688	0.00222	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GHRL—esophageal cancer	0.000685	0.00221	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—WIF1—esophageal cancer	0.000684	0.00221	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CXCL2—esophageal cancer	0.000672	0.00217	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GHRL—esophageal cancer	0.00067	0.00217	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—SST—esophageal cancer	0.000669	0.00216	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GHRL—esophageal cancer	0.000652	0.00211	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000651	0.0021	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000642	0.00207	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CSNK1A1—esophageal cancer	0.000631	0.00204	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—ANXA1—esophageal cancer	0.000625	0.00202	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000612	0.00198	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—SST—esophageal cancer	0.000608	0.00196	CbGpPWpGaD
Labetalol—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000603	0.00195	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GHRL—esophageal cancer	0.000592	0.00191	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PFN1—esophageal cancer	0.00059	0.00191	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—AKAP13—esophageal cancer	0.000573	0.00185	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—AKAP13—esophageal cancer	0.000561	0.00181	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KMT2D—esophageal cancer	0.000535	0.00173	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ELMO1—esophageal cancer	0.00053	0.00171	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PDE4D—esophageal cancer	0.000524	0.00169	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KMT2D—esophageal cancer	0.000524	0.00169	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—AKAP13—esophageal cancer	0.00052	0.00168	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—AKAP13—esophageal cancer	0.000518	0.00167	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PDE4D—esophageal cancer	0.000513	0.00166	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—AKAP13—esophageal cancer	0.000509	0.00165	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GNG7—esophageal cancer	0.000499	0.00161	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GNG7—esophageal cancer	0.000488	0.00158	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000478	0.00155	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ADCYAP1—esophageal cancer	0.000477	0.00154	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PDE4D—esophageal cancer	0.000476	0.00154	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PDE4D—esophageal cancer	0.000474	0.00153	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ADCYAP1—esophageal cancer	0.000467	0.00151	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PDE4D—esophageal cancer	0.000466	0.00151	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GNG7—esophageal cancer	0.000453	0.00146	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GNG7—esophageal cancer	0.000451	0.00146	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GNG7—esophageal cancer	0.000443	0.00143	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CXCL2—esophageal cancer	0.000439	0.00142	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—WWOX—esophageal cancer	0.000436	0.00141	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CXCL2—esophageal cancer	0.00043	0.00139	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—WWOX—esophageal cancer	0.000427	0.00138	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—XIAP—esophageal cancer	0.000422	0.00136	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FKBP1A—esophageal cancer	0.000415	0.00134	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000408	0.00132	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FKBP1A—esophageal cancer	0.000406	0.00131	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—WIF1—esophageal cancer	0.000406	0.00131	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—ANXA1—esophageal cancer	0.0004	0.00129	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CTNNA1—esophageal cancer	0.000399	0.00129	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CXCL2—esophageal cancer	0.000399	0.00129	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—SST—esophageal cancer	0.000397	0.00128	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CXCL2—esophageal cancer	0.000397	0.00128	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—WIF1—esophageal cancer	0.000397	0.00128	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CXCL2—esophageal cancer	0.00039	0.00126	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—SST—esophageal cancer	0.000389	0.00126	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GHRL—esophageal cancer	0.000387	0.00125	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GHRL—esophageal cancer	0.000379	0.00122	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000374	0.00121	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PSME1—esophageal cancer	0.000371	0.0012	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PSME2—esophageal cancer	0.000371	0.0012	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—ANXA1—esophageal cancer	0.000371	0.0012	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ANXA1—esophageal cancer	0.000369	0.00119	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CSNK1A1—esophageal cancer	0.000366	0.00118	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—ANXA1—esophageal cancer	0.000363	0.00117	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—SST—esophageal cancer	0.000361	0.00117	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SST—esophageal cancer	0.000359	0.00116	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—SST—esophageal cancer	0.000353	0.00114	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GHRL—esophageal cancer	0.000352	0.00114	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PFN1—esophageal cancer	0.00035	0.00113	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOTCH3—esophageal cancer	0.00035	0.00113	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GHRL—esophageal cancer	0.00035	0.00113	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—FBXW7—esophageal cancer	0.000344	0.00111	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GHRL—esophageal cancer	0.000344	0.00111	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PFN1—esophageal cancer	0.000343	0.00111	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000329	0.00106	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000329	0.00106	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ELMO1—esophageal cancer	0.000315	0.00102	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOTCH2—esophageal cancer	0.000314	0.00101	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ELMO1—esophageal cancer	0.000308	0.000995	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—AKAP13—esophageal cancer	0.000307	0.000994	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—AKAP13—esophageal cancer	0.000301	0.000972	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000284	0.000917	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PDE4D—esophageal cancer	0.000281	0.000909	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CA1—esophageal cancer	0.00028	0.000903	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.00028	0.000903	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TGFBR2—esophageal cancer	0.000278	0.0009	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000278	0.000897	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PDE4D—esophageal cancer	0.000275	0.000889	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GNG7—esophageal cancer	0.000267	0.000865	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SMAD4—esophageal cancer	0.000264	0.000852	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GNG7—esophageal cancer	0.000262	0.000846	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CA2—esophageal cancer	0.000256	0.000826	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—XIAP—esophageal cancer	0.000251	0.00081	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—XIAP—esophageal cancer	0.000245	0.000792	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000238	0.000768	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000238	0.000768	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CTNNA1—esophageal cancer	0.000237	0.000766	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CXCL2—esophageal cancer	0.000236	0.000762	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CTNNA1—esophageal cancer	0.000232	0.000749	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CXCL2—esophageal cancer	0.000231	0.000745	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PSME2—esophageal cancer	0.00022	0.000711	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PSME1—esophageal cancer	0.00022	0.000711	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ANXA1—esophageal cancer	0.000219	0.000708	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—HIF1A—esophageal cancer	0.000216	0.000697	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PSME2—esophageal cancer	0.000215	0.000696	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PSME1—esophageal cancer	0.000215	0.000696	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ANXA1—esophageal cancer	0.000214	0.000693	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SST—esophageal cancer	0.000213	0.000689	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SST—esophageal cancer	0.000208	0.000674	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.000208	0.000674	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOTCH3—esophageal cancer	0.000208	0.000671	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GHRL—esophageal cancer	0.000208	0.000671	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—KDR—esophageal cancer	0.000206	0.000667	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—FBXW7—esophageal cancer	0.000204	0.00066	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOTCH3—esophageal cancer	0.000203	0.000657	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GHRL—esophageal cancer	0.000203	0.000657	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—FBXW7—esophageal cancer	0.0002	0.000646	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000199	0.000644	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOTCH1—esophageal cancer	0.000194	0.000628	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000194	0.000626	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000189	0.00061	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOTCH2—esophageal cancer	0.000186	0.000602	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOTCH2—esophageal cancer	0.000182	0.000589	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.00018	0.000582	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—TPI1—esophageal cancer	0.00018	0.000582	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CREBBP—esophageal cancer	0.000176	0.000569	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—EGFR—esophageal cancer	0.000173	0.000559	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000173	0.000558	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000166	0.000537	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000165	0.000535	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TGFBR2—esophageal cancer	0.000165	0.000534	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000165	0.000532	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TGFBR2—esophageal cancer	0.000162	0.000522	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—NOS3—esophageal cancer	0.000158	0.00051	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000157	0.000506	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SMAD4—esophageal cancer	0.000156	0.000506	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SMAD4—esophageal cancer	0.000153	0.000495	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PIK3CA—esophageal cancer	0.00015	0.000486	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ERBB2—esophageal cancer	0.000148	0.000477	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000147	0.000475	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.00014	0.000451	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000138	0.000446	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.000131	0.000423	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ENO1—esophageal cancer	0.000131	0.000423	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CCND1—esophageal cancer	0.00013	0.000421	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000129	0.000417	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000129	0.000417	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—HIF1A—esophageal cancer	0.000128	0.000414	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDKN1A—esophageal cancer	0.000126	0.000407	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—HIF1A—esophageal cancer	0.000125	0.000405	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—KDR—esophageal cancer	0.000122	0.000396	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EP300—esophageal cancer	0.00012	0.000388	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—KDR—esophageal cancer	0.00012	0.000387	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOTCH1—esophageal cancer	0.000115	0.000373	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOTCH1—esophageal cancer	0.000113	0.000365	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000111	0.00036	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000105	0.000338	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CREBBP—esophageal cancer	0.000105	0.000338	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MYC—esophageal cancer	0.000105	0.000338	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—EGFR—esophageal cancer	0.000103	0.000332	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CREBBP—esophageal cancer	0.000102	0.000331	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EGFR—esophageal cancer	0.000102	0.00033	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—EGFR—esophageal cancer	0.0001	0.000325	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—PIK3CA—esophageal cancer	9.82e-05	0.000317	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—PIK3CA—esophageal cancer	9.6e-05	0.00031	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—HMOX1—esophageal cancer	9.55e-05	0.000309	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—NOS3—esophageal cancer	9.36e-05	0.000303	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ABCB1—esophageal cancer	9.16e-05	0.000296	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—NOS3—esophageal cancer	9.16e-05	0.000296	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PIK3CA—esophageal cancer	8.92e-05	0.000288	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PIK3CA—esophageal cancer	8.87e-05	0.000287	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ERBB2—esophageal cancer	8.76e-05	0.000283	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PIK3CA—esophageal cancer	8.72e-05	0.000282	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TP53—esophageal cancer	8.58e-05	0.000277	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ERBB2—esophageal cancer	8.56e-05	0.000277	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CCND1—esophageal cancer	7.74e-05	0.00025	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CCND1—esophageal cancer	7.57e-05	0.000245	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDKN1A—esophageal cancer	7.48e-05	0.000242	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDKN1A—esophageal cancer	7.32e-05	0.000237	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EP300—esophageal cancer	7.12e-05	0.00023	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EP300—esophageal cancer	6.97e-05	0.000225	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MYC—esophageal cancer	6.2e-05	0.000201	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—CREBBP—esophageal cancer	6.12e-05	0.000198	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MYC—esophageal cancer	6.07e-05	0.000196	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGFR—esophageal cancer	6.07e-05	0.000196	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGFR—esophageal cancer	5.94e-05	0.000192	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—NOS3—esophageal cancer	5.48e-05	0.000177	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PIK3CA—esophageal cancer	5.27e-05	0.00017	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PIK3CA—esophageal cancer	5.15e-05	0.000167	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TP53—esophageal cancer	5.1e-05	0.000165	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTGS2—esophageal cancer	5.02e-05	0.000162	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TP53—esophageal cancer	4.98e-05	0.000161	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—EP300—esophageal cancer	4.17e-05	0.000135	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PIK3CA—esophageal cancer	3.09e-05	9.97e-05	CbGpPWpGaD
